Pdf 695.43 K

Total Page:16

File Type:pdf, Size:1020Kb

Pdf 695.43 K Iran. J Biotechnol. January 2021;19(1): e2618 DOI: 10.30498/IJB.2021.2618 Research Article Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis and B. ovis: Comparing Cell-Mediated and Protective Immune Responses Elicited by pCDNA3.1 and pVAX1 DNA Vaccines Coding for Omp31 of Brucella melitensis Naser Harzandi1*, Haniyeh Aghababa2,3, Nima Khoramabadi2, Termeh Tabaraie4 1Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran. 2Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 3Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. 4Department of Cardiology, Charité Medical University of Berlin, Berlin, Germany. *Corresponding author: Naser Harzandi, - Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran. Tel:+98-2634182637, Fax:+98-2634418156, E-mail: [email protected] Background: Brucella spp. are intracellular pathogens, therefore cell-mediated immunity is the main response to inhibit survival and growth of the bacteria in vertebrate host. Objective: Many eukaryotic plasmid vectors are being used in setting up DNA vaccines which may show different efficiencies in same conditions. This is important in designing the vaccines and immunization strategies. We looked into the probable differences of immune responses induced by different eukaryotic DNA plasmid vectors (pcDNA3.1 and pVAX1) harboring the same Omp31 gene of B. melitensis. Materials and Methods: Female BALB/c mice were immunized with pcDNA-omp31 and pVAX-omp31 and further boosted with recombinant Omp31. Subclasses of specific serum IgG against the rOmp31 were measured by ELISA. Cytokines responses to rOmp31 in Splenocyte cultures of the immunized mice were evaluated by measuring the production of IL- 4, IL-10, IL-12 and IFN-γ. Protective responses of the immunized mice were evaluated by intraperitoneal challenge with pathogenic Brucella melitensis 16M and Brucella ovis PA76250. Results: Both DNA vaccine candidates conferred potent Th1-type responses with higher levels of cytokines and immunoglobulins observed in mice immunized with pVAX-omp31. Although pcDNA-omp31 and pVAX-omp31 both elicited protective immunity, mice immunized with the latter showed a higher protection against both B. melitensis and B. ovis PA76250. Conclusion: The results of this study highlight the significant differences between efficiency of diverse plasmid backbones in DNA vaccines which code for an identical antigen. Comparing various plasmid vectors should be considered as an essential part of the studies aiming construction of DNA vaccines for intracellular pathogens. Keywords: Brucella, DNA vaccine, Omp31, pCDNA3.1, pVAX1 1. Background after consumption of contaminated dairy or food or by Brucella spp. are Gram-negative, facultative contacts with infected animals (5). There is no licensed intracellular pathogens and cause brucellosis in human vaccines available for prevention of human brucellosis and animals. This pathogen is mainly localized at the and disease prevention principally relies on control reticuloendothelial system of vertebrate hosts (1-3). of animal brucellosis by vaccination (6, 7). The most B. melitensis is the most pathogenic member of the widely used vaccines for control of animal brucellosis genus and responsible for severe disease in humans, are the live attenuated strains, B. melitensis Rev1, and B. although the preferred hosts are goats, sheep, cows, abortus S19 (8). Live attenuated vaccines are pathogenic dogs and camels (4). Brucella infections occur mainly for humans; they also cause serological interference Copyright © 2021 The Author(s); Published by National Institute of Genetic Engineering and Biotechnology. This is an open access article, distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses /by-nc/4.0/) which permits others to copy and redistribute material just in noncommercial usages, provided the original work is properly cited. Harzandi N et al. with diagnostic methods in vaccinated animals (9, 10). collection at Pasteur Institute of Iran. E. coli DH5α routinely Brucella pathogens can escape recognition by the host is cultured using LB medium. Brucella melitensis Rev1, innate immune responses and further use sophisticated B. melitensis 16M and B. ovis PA76250 were stored in strategies to avoid intracellular destruction after being culture collection at Department of Bacteriology (Tarbiat phagocytosed by host macrophages. This, enables them Modares University). Brucella strains were cultured to survive and establish a persistent infection (2, 11, routinely on Brucella agar (Merck) and incubated at 37 12). Since these pathogens survive in macrophages, °C. These pathogenic bacteria were handled according to cell-mediated immunity is necessary for activation of biosafety level 2 practices and regulations. infected macrophages and clearance of the pathogen and formation of active CD8+ cytotoxic T-lymphocytes 3.3. Recombinant Omp31 (2, 13). Many reports are available on using subunit Recombinant Omp31 (rOmp31) was previously vaccines consisting of Brucella outer membrane produced in our lab and preserved in -80 °C as a proteins and their ability to elicit Th1-type responses concentrated stock of ~20±1 mg.mL-1. and partial protection against pathogenic strains (14- 16). Many protein antigens including outer membrane 3.4. Construction and Preparation of DNA Vaccines proteins and intracellular ones reported to induce The complete coding sequence of Omp31 was inserted potent cytokine and antibody responses especially between BamHI and XhoI recognition sequences in IFN-γ, IL-12 and IgG2a - immunological mediators pVAX1TM (InvitrogenTM, V260-20) and pcDNATM3.1 which are important for inhibiting Brucella infection (InvitrogenTM, V790-20). Specific primers including in hosts (17). The need for induction of more potent restriction sites at the 5’ ends were used (bmO31dnF- cell-mediated immunity has led some researchers to 5’-AAT GGA TCC ACC ACC ATG AAC TCC GTA use DNA vaccines as they are believed to elicit Th1- ATT TTG GCG TCC ATC-5› and bmO31dnR- 5’-ACA type responses (18-22). A neglected factor remains to CTC GAG TTA GAA CTT GTA GTT CAG ACC GAC be investigated which is the influence of the plasmid GCG-5›) with the Kozak consensus sequence considered vector used for constructing the DNA vaccine. Different before the ATG codon (underlined) (26). Recombinant plasmid vectors are used to compose DNA vaccines and plasmids named as pVAX-omp31 and pcDNA-omp31 they may have variable efficiencies in stimulating host were confirmed by sequencing. Recombinant plasmids immune system. This could be of crucial importance to were amplified inE. coli DH5α host and were extracted enlighten whether it is necessary to compare different and purified by EndoFree Plasmid Giga Kit (QIAGEN, DNA plasmid backbones for a single antigen or not. Catalog no. 12391) according to the manufacturer instructions. Quality and quantity of the purified plasmids 2. Objectives were assessed using NanoDrop spectrophotometer This study was aimed to present a research model for (NanoDropTM 2000; Thermo Sientific). To confirm the exploring the efficiency of different eukaryotic DNA recombinant plasmids can express the inserted omp31 plasmids (pVAX1TM and pcDNATM3.1) for eliciting cell- gene, they were separately transfected to the COS-7 mediated responses against Omp31 (23, 24) – a well- cell line (ATCC CRL-1651, Pasteur Institute of Iran) by studied antigen of Brucellae – as DNA vaccine. In this Lipofectamine® 2000 reagent (Life Technologies) and model, the immunogenic Omp31 is the constant antigen protein expression was traced through western blotting to study the effect of plasmid vector backbone selection as described previously (24, 27). Rabbit polyclonal on immunological responses elicited in BALB/c mice. antiserum against rOmp31 (Anti-Omp31; produced in our laboratory) (1:5000) was used for tracing Omp31 3. Materials and Methods expression in transfected COS-7 cells. Membranes were then treated with goat anti-rabbit IgG (Sigma) 3.1. Animal Model and after being washed thoroughly, developed with Six- to eight-weeks old female BALB/c mice were enhanced chemiluminescent (ECL) substrate under acquired from Laboratory Animal Production Center standard conditions. Appearance of fluorescent bands (Pasteur Institute, Iran). Mice were maintained under was recorded on radiographic films (28). standard laboratory conditions and kept one week for adaptation before experiments (25). 3.5. Immunization of Mice Six- to eight-week old female BALB/c mice were 3.2. Bacterial Strains and Culture Conditions anesthetized with Ketamine/Xylazine intraperitoneally Escherichia coli DH5α was obtained from the culture and immunized intramuscularly with 100μg of Iran. J Biotechnol. January 2021;19(1): e2618 41 Harzandi N et al. pcDNA-omp31 (Group I), pVAX-omp31 (Group II), 24-well plates were examined by specific ELISA for intact pcDNA3.1 (Group III) or pVAX1 (Group IV) in mouse IL-4, IL-10, IL-12 and IFN-γ (R&D) as triplicate separate groups of 15 mice. Mice were injected with for each mouse. the same plasmids four times in two-week intervals (24). Thereafter, mice which were immunized with 3.8. Protection Assessment pcDNA-omp31 (Group I) and pVAX-omp31 (Group Four weeks after the last booster dose, 8 mice from II) were boosted
Recommended publications
  • Medical Management of Biologic Casualties Handbook
    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Fourth Edition February 2001 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES ¨ FORT DETRICK FREDERICK, MARYLAND 1 Sources of information: National Response Center 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Help line: 1-410-436-4484 or (Edgewood Ops Center - for military use) DSN 584-4484 USAMRIID Emergency Response Line: 1-888-872-7443 CDC'S Bioterrorism Preparedness and Response Center: 1-770-488-7100 John's Hopkins Center for Civilian Biodefense: 1-410-223-1667 (Civilian Biodefense Studies) An Adobe Acrobat Reader (pdf file) version and a Palm OS Electronic version of this Handbook can both be downloaded from the Internet at: http://www.usamriid.army.mil/education/bluebook.html 2 USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Fourth Edition February 2001 Editors: LTC Mark Kortepeter LTC George Christopher COL Ted Cieslak CDR Randall Culpepper CDR Robert Darling MAJ Julie Pavlin LTC John Rowe COL Kelly McKee, Jr. COL Edward Eitzen, Jr. Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 3 PREFACE TO THE FOURTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations. Since the first edition in 1993, the awareness of biological weapons in the United States has increased dramatically.
    [Show full text]
  • Medical Management of Biological Casualties Handbook
    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES FORT DETRICK FREDERICK, MARYLAND Emergency Response Numbers National Response Center: 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Helpline: 1-410-436-4484 or (Edgewood Ops Center – for military use) DSN 584-4484 USAMRIID’s Emergency Response Line: 1-888-872-7443 CDC'S Emergency Response Line: 1-770-488-7100 Handbook Download Site An Adobe Acrobat Reader (pdf file) version of this handbook can be downloaded from the internet at the following url: http://www.usamriid.army.mil USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 Lead Editor Lt Col Jon B. Woods, MC, USAF Contributing Editors CAPT Robert G. Darling, MC, USN LTC Zygmunt F. Dembek, MS, USAR Lt Col Bridget K. Carr, MSC, USAF COL Ted J. Cieslak, MC, USA LCDR James V. Lawler, MC, USN MAJ Anthony C. Littrell, MC, USA LTC Mark G. Kortepeter, MC, USA LTC Nelson W. Rebert, MS, USA LTC Scott A. Stanek, MC, USA COL James W. Martin, MC, USA Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 PREFACE TO THE SIXTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • The Use of Live Vaccine for Vaccination of Human Beings Against Brucellosis in the USSR
    Bull. Org. mond. Santeh 1961 2 85-89 Bull. Wld HIth Org. J The Use of Live Vaccine for Vaccination of Human Beings against Brucellosis in the USSR P. A. VERSHILOVA, M.D.1 The great majority of human brucellosis cases in the USSR are caused by contact with infected sheep and goats. Extensive action has been taken to prevent human infection and to reduce the incidence among farm animals, the main prophylactic measure in recent years being vaccination with live brucellosis vaccine. The author summarizes the steps leading to the development of a satisfactory vaccine and gives a brief description of the method of preparation. Discussing the results obtained, she states that there has been a nearly 60 %,0 reduction in the number of human cases over the period 1952-58. The subcutaneous route of administration is usually resorted to, but preliminary figures suggest that cutaneous vaccination is equally effective immunogenically, although in persons who have sujJeredfrom active brucellosis it causes strong reactions and may lead to exacerba- tion of the disease. Research is going forward into the development ofa cutaneous vaccine capable ofgeneral use. INTRODUCTION and at the same time measures of prophylaxis have been organized to prevent human infection. Since Epizootiological and epidemiological data now 1953-54, wherever there is a risk of human infection available show that brucellosis is distributed quite with brucellosis of goats and sheep, the main pro- widely in many countries. In the USSR brucellosis phylactic measure taken has been the vaccination of of all three types is encountered, but the bovine and human beings with live brucellosis vaccine.
    [Show full text]
  • The Landscape of Vaccines in China: History, Classification, Supply, and Price
    Zheng et al. BMC Infectious Diseases (2018) 18:502 https://doi.org/10.1186/s12879-018-3422-0 RESEARCHARTICLE Open Access The landscape of vaccines in China: history, classification, supply, and price Yaming Zheng1, Lance Rodewald2, Juan Yang3, Ying Qin1, Mingfan Pang1, Luzhao Feng1 and Hongjie Yu1,3* Abstract Background: Vaccine regulation in China meets World Health Organization standards, but China’s vaccine industry and immunization program have some characteristics that differ from other countries. We described the history, classification, supply and prices of vaccines available and used in China, compared with high-and middle-incomes countries to illustrate the development of Chinese vaccine industry and immunization program. Methods: Immunization policy documents were obtained from the State Council and the National Health and Family Planning Commission (NHFPC). Numbers of doses of vaccines released in China were obtained from the Biologicals Lot Release Program of the National Institutes for Food and Drug Control (NIFDC). Vaccine prices were obtained from Chinese Central Government Procurement (CCGP). International data were collected from US CDC, Public Health England, European CDC, WHO, and UNICEF. Results: Between 2007 and 2015, the annual supply of vaccines in China ranged between 666 million and 1,190 million doses, with most doses produced domestically. The government’s Expanded Program on Immunization (EPI) prevents 12 vaccine preventable diseases (VPD) through routine immunization. China produces vaccines that are in common use globally; however, the number of routinely-prevented diseases is fewer than in high- and middle- income countries. Contract prices for program (EPI) vaccines ranged from 0.1 to 5.7 US dollars per dose - similar to UNICEF prices.
    [Show full text]
  • Results of Pre-Clinical and Clinical Tests of Organic Hydroxyapatite As Adjuvant of Bacterial Vaccine
    Advances in Animal and Veterinary Sciences Research Article Results of Pre-Clinical and Clinical Tests of Organic Hydroxyapatite as Adjuvant of Bacterial Vaccine VALERY ALEXANDROVICH AGOLTSOV, OLGA MIKHAILOVNA POPOVA, STEPAN YURIEVICH VESELOVSKY, ALEXEI ALEXANDROVICH CHASTOV, ALEXANDER MEFODIEVICH SEMIVOLOS, NATALIYA VICTOROVNA SOLOTOVA* Department of Veterinary Medicine, Saratov State Agrarian University named after N.I. Vavilov, Russia, 410012, Saratov, Teatralnaya square, Russia. Abstract | Vaccination continues to be one of the most effective ways to protect against infectious diseases; therefore, there is a need to develop new vaccines that have low cost and are used either once or for long periods of time.The current study aims to test organic hydroxyapatite in bacterial vaccines on laboratory and farm animals and determine its adjuvant and immunogenic properties. In pre-clinical tests, white mongrel mice weighing 18-20g and rats weighing 250-300g were used. Adjuvant (organic hydroxyapatite) separately and as part of vaccines was administered subcutaneously, intraperitoneally and intramuscularly at a dose of 0.5 ml. Clinical tests of adjuvant were carried out on Holstein-Friesian cows and calves. Experimental vaccines were used: 1) a split-conjugated vaccine against animal brucellosis (as antigens it included the components of brucella (Br. Abortus); 2) a vaccine against mastitis of cows. Results showed that PhA, neutrophils and monocytes in the blood smears of the control group were 1.4 times lower, and twice as much compared to the vaccine without the adjuvant. The maximum PhI(FI) was observed in animals immunized with a split-conjugated vaccine against brucellosis of animals with the adjuvant. The disappearance of vaccine antibody titer in the blood after 30 days was stated, which is positive in the diagnosis of brucellosis.
    [Show full text]
  • Russian Vaccines Against Especially Dangerous Bacterial Pathogens
    Emerging Microbes and Infections (2014) 3, e86; doi:10.1038/emi.2014.82 OPEN ß 2014 SSCC. All rights reserved 2222-1751/14 www.nature.com/emi REVIEW Russian vaccines against especially dangerous bacterial pathogens Valentina A Feodorova1, Lidiya V Sayapina2, Michael J Corbel3 and Vladimir L Motin4 In response to the epidemiological situation, live attenuated or killed vaccines against anthrax, brucellosis, cholera, glanders, plague and tularemia were developed and used for immunization of at-risk populations in the Former Soviet Union. Certain of these vaccines have been updated and currently they are used on a selective basis, mainly for high risk occupations, in the Russian Federation. Except for anthrax and cholera these vaccines currently are the only licensed products available for protection against the most dangerous bacterial pathogens. Development of improved formulations and new products is ongoing. Emerging Microbes and Infections (2014) 3, e86; doi:10.1038/emi.2014.82; published online 17 December 2014 Keywords: anthrax; brucellosis; cholera; pathogens; glanders; plague; tularemia; vaccine INTRODUCTION veterinary measures to control these diseases. Although some are History of especially dangerous bacterial pathogens (EDP) in Russia now of reduced importance, many of these vaccines still play a role The Russian Empire and subsequently the Former Soviet Union (FSU) in public health programmes and protection of individuals in high comprised an enormous continuous land area extending across two risk occupations. For the past three decades these vaccines have continents. Even today the Russian Federation covers a vast area been included in the national human immunization schedule for extending across Europe and Asia and including diverse environments use according to the epidemiological situation.
    [Show full text]
  • Current Opinion in Infectious Diseases Was Launched in 1988
    October 2007, Volume 20, Issue 5, pp.449-559 Editorial introductions vii Editorial introductions. Tropical and travel-associated diseases 449 Etiology of travel-related fever. Mary E Wilson; David O Freedman 454 Meningococcal vaccine in travelers. Annelies Wilder-Smith 461 Preerythrocytic malaria vaccine development. Sebastian A Mikolajczak; Ahmed SI Aly; Stefan HI Kappe 467 Asexual blood-stage malaria vaccine development: facing the challenges. Blaise Genton; Zarifah H Reed 476 Mosquito stage, transmission blocking vaccines for malaria. Allan Saul 482 Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Stephen D Lawn 489 Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. Hector H Garcia; Pedro L Moro; Peter M Schantz 495 Crimean-Congo hemorrhagic fever. Regina Vorou; Ioannis N Pierroutsakos; Helen C Maltezou Gastrointestinal infections 501 Rotavirus vaccines: entering a new stage of deployment. Osamu Nakagomi; Nigel A Cunliffe 508 The normal intestinal microbiota. Julian Marchesi; Fergus Shanahan 514 The second century of Campylobacter research: recent advances, new opportunities and old problems. Nick Dorrell; Brendan W Wren 519 Below the belt: new insights into potential complications of HIV- 1/schistosome coinfections. W Evan Secor; J Bruce Sundstrom 524 Intestinal cestodes. Philip Craig; Akira Ito Current World Literature Bibliography 533 Current World Literature. Editorial introductions Current Opinion in Infectious Diseases was launched in 1988. entitled ‘‘Endemic Infectious Diseases of the Peruvian It is part of a successful series of review journals whose Amazon’’. His research is supported by grants from the unique format is designed to provide a systematic and United States Public Health Service, National Institutes critical assessment of the literature as presented in the of Health.
    [Show full text]
  • Thesis.Pdf (732.5Kb)
    INTRODUCTION The first disease for which a bacterial agent was found to be the cause was anthrax (Greek meaning coal for the characteristic eschars found on the skin) (11,19). The disease is thought to have been the cause of the fifth and sixth plagues that attacked the livestock and people of Egypt in Exodus 9 (5,11,17). Casimir Davaine first isolated the bacterium, Bacillus anthracis, in 1850 (11). In 1876, Robert Koch developed a method for culturing pure B. anthracis and in 1881, Louis Pasteur created the first major vaccine against the disease in livestock (5,11). Despite the existence of vaccines against the disease since the 1870’s, anthrax remains a serious threat to livestock and even humans in the developing countries of Asia, Africa and South America (19). B. anthracis, the causative bacterial agent of anthrax, is believed to be part of the biological arsenals of at least ten nations. With the current world environment and the unpredictable threat of terrorism, it would seem prudent to include biological warfare defense measures into our national defense arsenals (8,11). The bacteria in the genus Bacillus are characterized as large, gram-positive, rod- shaped organisms (31). B. anthracis occurs singly or in pairs in tissue, and in culture appear in long strings giving a classic “boxcar” look. The anthrax bacterium is never motile (19). B. anthracis is a spore-forming bacterium whose spores can survive in dry form for indefinite periods of time and then be released into the atmosphere with the capability of causing disease (8). Spore formation occurs after host death.
    [Show full text]
  • Occupational Infection to Brucella Abortus B19 Vaccine Despite Antimicrobial Prophylaxis
    ORIGINAL ARTICLE Occupational infection to Brucella abortus B19 vaccine despite antimicrobial prophylaxis Infecção ocupacional pela cepa vacinal de Brucella abortus B19 apesar de profilaxia antimicrobiana Alexandre Sampaio Moura1 , Letícia Mattos Menezes2 , Marcelle Amaral de Matos3 , Cynthya Magalhães Costa3 , Bruna Arantes Borges3 ABSTRACT The authors report the case of a veterinarian who acquired brucellosis infection by accidental exposure to Brucella abortus vaccine (BRUCEL-VET B19) while performing animal vaccination. Antibiotic prophylaxis with doxycycline and rifampin for six weeks was indicated, but rifampin was discontinued after 10 days due to gastrointestinal in- tolerance. Despite prophylaxis, the patient seroconverted after 30 days, but was asymptomatic and did not require additional antibiotic therapy. Post-exposure prophylaxis of Brucella is not free from side effects and asymptomatic seroconversion can occur despite prophylaxis. Keywords: Brucellosis; Occupational Exposure; Post-Exposure Prophylaxis. RESUMO Os autores relatam o caso de um veterinário que adquiriu infecção por brucelose por exposição acidental à vacina Brucellaabortus (BRUCEL-VET B19) durante a vacinação animal. A profilaxia antibiótica com doxiciclina e rifampici- na por seis semanas foi indicada, mas a rifampicina foi descontinuada após 10 dias devido à intolerância gastroin- testinal. A profilaxia pós-exposição de Brucella não está isenta de efeitos colaterais e a soroconversãoassintomática pode ocorrer apesar da profilaxia. Palavras-chave: Brucelose; Exposição Ocupacional; Profilaxia Pós-Exposição. INTRODUCTION in about 20 to 30% of the cases1,3. There is fre- quent involvement of bones and joints resulting in Brucellosis is a bacterial zoonosis responsible focal complications such as sacroiliitis, spondylitis, for more than half a million new human cases annu- peripheral arthritis and osteomyelitis1.
    [Show full text]
  • Bovine Brucellosis Vaccine Strain S19 Detected in Calves Before Vaccination
    Bovine brucellosis vaccine strain S19 detected in calves before vaccination C. Mantovani1,2, C.O. Soares2, L.R. dos Santos2 and G.M.S. Rosinha2 1 Biotecnologia e Biodiversidade Rede Pró-Centro-Oeste, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil 2 Laboratório de Engenharia Genética Animal, Centro Nacional de Pesquisa em Gado de Corte, Empresa Brasileira de Pesquisa Agropecuária- EMBRAPA, Campo Grande, MS, Brasil Corresponding author: G.M.S. Rosinha E-mail: [email protected] Genet. Mol. Res. 19 (3): gmr18659 Received June 05, 2020 Accepted August 03, 2020 Published August 27, 2020 DOI http://dx.doi.org/10.4238/gmr18659 ABSTRACT. Bovine brucellosis is a zoonotic disease that has considerable economic impact on the market of products such as meat and milk. As Brazil has one of the largest cattle herds in the world, this disease is a significant agricultural and public health concern. In 2001, Brazil launched the National Program of Control and Eradication of Animal Brucellosis and Tuberculosis. This program included the vaccination of 3-8 month old calves using the smooth and attenuated S19 strain, as well as monitoring with serological tests. There have been reports of excretion and persistence of S19. In this context, the objective of this study was to monitor the persistence of the S19 vaccine strain in blood samples from vaccinated calves. Seroconversion was investigated to evaluate the vaccine immunogenicity. PCR assays of blood and serum were run at at: "day zero" (before vaccination), 1 to 15 days after vaccination and every month until 12 months, totaling 28 collections for each of 10 calves.
    [Show full text]
  • BRUCELLOSIS (Undulant Fever, Malta Fever, Mediterranean Fever, Bang's Disease)
    BRUCELLOSIS (Undulant Fever, Malta Fever, Mediterranean Fever, Bang's Disease) REPORTING INFORMATION • Class B: Report by the close of the next business day after the case or suspected case presents and/or a positive laboratory result to the local public health department where the patient resides. If patient residence is unknown, report to the local public health department in which the reporting health care provider or laboratory is located. • Reporting Form(s) and/or Mechanism: o The Ohio Disease Reporting System (ODRS) should be used to report lab findings to the Ohio Department of Health (ODH). For healthcare providers without access to ODRS, you may use the Ohio Confidential Reportable Disease Form (HEA 3334, rev. 1/09 http://www.odh.ohio.gov/wps/portal/gov/odh/know-our-programs/ infectious-disease-control-manual/forms/form-confidential-reportable- disease) • The CDC Brucellosis Case Report Form is required for completion by the local health department. Information collected from the form should be entered into ODRS and faxed to the Ohio Department of Health (ODH) Outbreak Response & Bioterrorism Investigation Team (ORBIT) 614-564-2456. The mailing address for this form is: ODH Outbreak Response & Bioterrorism Investigation Team (ORBIT), 246 N. High St., Columbus, OH 43215. • Key fields for ODRS reporting include: import status (whether the infection was travel-associated or Ohio-acquired), date of illness onset, and all the fields in the AGENTSEpidemiology module. Brucella abortus, Brucella canis, Brucella ceti, Brucella melitensis. Brucella pinnepedialis, and Brucella suis. CASE DEFINITION Clinical Description An illness characterized by acute or insidious onset of fever and one or more of the following: night sweats, arthralgia, headache, fatigue, anorexia, myalgia, weight loss, arthritis/spondylitis, meningitis, or focal organ involvement (endocarditis, orchitis/epididymitis, hepatomegaly, splenomegaly).
    [Show full text]